Connor, Clark & Lunn Investment Management (CC&L)’s Arcturus Therapeutics ARCT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-74,830	Closed	-$1.82M	–	1424
2024 Q2	$1.82M	Sell	74,830 -41,115	-35%	-$1.25M	0.01%	676
2024 Q1	$3.92M	Buy	115,945 +16,203	+16%	+$574K	0.02%	490
2023 Q4	$3.14M	Buy	99,742 +64,520	+183%	+$1.53M	0.01%	552
2023 Q3	$900K	Sell	35,222 -8,412	-19%	-$259K	﹤0.01%	852
2023 Q2	$1.25M	Buy	+43,634	New	+$1.19M	0.01%	734
2022 Q3	–	Sell	-19,276	Closed	-$303K	–	1105
2022 Q2	$303K	Sell	19,276 -35,324	-65%	-$693K	﹤0.01%	861
2022 Q1	$1.47M	Sell	54,600 -33,299	-38%	-$850K	0.01%	580
2021 Q4	$3.25M	Buy	87,899 +9,817	+13%	+$400K	0.02%	421
2021 Q3	$3.73M	Buy	+78,082	New	+$3.5M	0.02%	403

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ARCT Position: Q3 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Arcturus Therapeutics (ARCT) in Q3 2024, closing a stake of 74,830 shares — an estimated $1.82M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ARCT in Q3 2021 and held it in 9 quarters. The position peaked at $3.92M in Q1 2024. 164 funds tracked by Wall St. Rank hold ARCT as of Q3 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Arcturus Therapeutics position as of Q3 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 74,830 Arcturus Therapeutics shares in Q3 2024, an estimated $1.82M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Arcturus Therapeutics in Q3 2021 and held it in 9 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Arcturus Therapeutics position peaked at $3.92M in Q1 2024.
164 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2024, filed 8 Nov 2024.